Prospective clinical study of moxibustion in the treatment of Parkinson's disease

注册号:

Registration number:

ITMCTR2000002995

最近更新日期:

Date of Last Refreshed on:

2020-02-11

注册时间:

Date of Registration:

2020-02-11

注册号状态:

Registration Status:

预注册

Prospective registration

注册题目:

艾灸治疗帕金森病的前瞻性临床研究

Public title:

Prospective clinical study of moxibustion in the treatment of Parkinson's disease

注册题目简写:

English Acronym:

研究课题的正式科学名称:

艾灸治疗帕金森病的前瞻性临床研究

Scientific title:

Prospective clinical study of moxibustion in the treatment of Parkinson's disease

研究课题的正式科学名称简写:

Scientific title acronym:

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

ChiCTR2000029745 ; ChiMCTR2000002995

申请注册联系人:

朱美玲

研究负责人:

朱美玲

Applicant:

Zhu Meiling

Study leader:

Zhu Meiling

申请注册联系人电话:

Applicant telephone:

+86 13312996033

研究负责人电话:

Study leader's telephone:

+86 13312996033

申请注册联系人传真 :

Applicant Fax:

+86 0755-27802542

研究负责人传真:

Study leader's fax:

+86 0755-27802542

申请注册联系人电子邮件:

Applicant E-mail:

48506106@qq.com

研究负责人电子邮件:

Study leader's E-mail:

48506106@qq.com

申请单位网址(自愿提供):

Study leader's website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website
(voluntary supply):

申请注册联系人通讯地址:

深圳市宝安区裕安二路25号

研究负责人通讯地址:

深圳市宝安区裕安二路25号

Applicant address:

25 Second Yu'an Road, Bao'an District, Shenzhen, Guangdong

Study leader's address:

25 Second Yu'an Road, Bao'an District, Shenzhen, Guangdong

申请注册联系人邮政编码:

Applicant postcode:

518133

研究负责人邮政编码:

Study leader's postcode:

518133

申请人所在单位:

深圳市宝安区中医院

Applicant's institution:

Traditional Chinese Medicine Hospital of Bao'an District, Shenzhen

是否获伦理委员会批准:

Approved by ethic committee:

伦理委员会批件文号:

Approved No. of ethic committee:

KY-2019-006-01

伦理委员会批件附件:

Approved file of Ethical Committee:

View

批准本研究的伦理委员会名称:

深圳市宝安区中医院医学伦理委员会

Name of the ethic committee:

Medical Ethics Committee of Traditional Chinese Medicine Hospital of Bao'an District, Shenzhen

伦理委员会批准日期:

Date of approved by ethic committee:

2020/1/17 0:00:00

伦理委员会联系人:

傅诗书

Contact Name of the ethic committee:

Fu Shishu

伦理委员会联系地址:

深圳市宝安区裕安二路25号

Contact Address of the ethic committee:

25 Second Yu'an Road, Bao'an District, Shenzhen, Guangdong

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

深圳市宝安区中医院

Primary sponsor:

Traditional Chinese Medicine Hospital of Bao'an District

研究实施负责(组长)单位地址:

深圳市宝安区裕安二路25号

Primary sponsor's address:

25 Second Yu'an Road, Bao'an District, Shenzhen, Guangdong

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

广东

市(区县):

深圳

Country:

China

Province:

Guangdong

City:

Shenzhen

单位(医院):

深圳市宝安区中医院

具体地址:

宝安区裕安二路25号

Institution
hospital:

Traditional Chinese Medicine Hospital of Bao'an District

Address:

25 Second Yu'an Road, Bao'an District

经费或物资来源:

广东省中医药管理局

Source(s) of funding:

Guangdong Province Traditional Chinese Medicine Administration

研究疾病:

帕金森病

研究疾病代码:

Target disease:

Parkinson's disease

Target disease code:

研究类型:

Study type:

干预性研究

Interventional study

研究设计:

Study design:

随机平行对照

randomized controlled trial(parallel group design)

研究所处阶段:

Study phase:

探索性研究/预试验

Pilot clinical trial

研究目的:

基于腧穴的特异性,进行艾灸治疗帕金森病的前瞻性临床研究,探索艾灸治疗帕金森病的临床研究,阐述艾灸治疗帕金森病运动与非运动症状的中医及西医机制。

Objectives of Study:

Based on the specificity of acupoints, a prospective clinical study of moxibustion in treating Parkinson's disease was conducted to explore the appropriate syndrome types of moxibustion in treating Parkinson's disease, and the mechanism of traditional Chinese medicine and western medicine for moxibustion in the treatment of exercise and non-motor symptoms of Parkinson's disease was explained.

药物成份或治疗方案详述:

Description for medicine or protocol of treatment in detail:

纳入标准:

(1)符合中西医诊断标准; (2)Hoehn-yahr(H-Y)分级1-3级; (3)年龄在70岁以下; (4)帕金森病程≥6个月; (5)口服多巴丝肼片剂量稳定至少30d,且不调整用药方案; (6)自愿参加并签署知情同意书。

Inclusion criteria

(1) All enrolled patients in accordance with diagnostic criteria. (2) Patients with Hoehn-yahr (H-Y) grade 1 to 3. (3) Patientsage under 70 years. (4) Duration of Parkinson over 6 months. (5) Patients take pasta hydrazine tablets at least 30 daysand the medication regimen was not adjusted. (6) Patients sign informed consent.

排除标准:

(1)各种继发性帕金森综合征及帕金森叠加综合征及Hoehn-yahr(H-Y)分级>3级; (2)伴有痴呆、精神障碍等无法交流与配合的患者; (3)严重脑血管或脑外伤、脑手术病史; (4)严重心、肺、肝、肾等全身器质性疾病及内分泌疾病和代谢障碍性疾病; (5)过敏体质或已知对艾灸过敏者; (6)已行DBS术者。

Exclusion criteria:

(1) Various secondary Parkinson's syndrome, Parkinson's syndrome, and Hoehn-yahr (H-Y) > 3. (2) Patients with dementia and mental disorders and unable to communicate and cooperate. (3) Patient has a history of severe brain trauma and brain surgery. (4) Patients have severe systemic organic diseases such as heart, lung, liver, kidney, endocrine diseases and metabolic disorders. (5) Patients cannot receive moxibustion.

研究实施时间:

Study execute time:

From 2021-08-10

To      2022-12-31

征募观察对象时间:

Recruiting time:

From 2021-08-10

To      2022-12-31

干预措施:

Interventions:

组别:

治疗组

样本量:

35

Group:

experimental group

Sample size:

干预措施:

标准治疗+艾灸

干预措施代码:

002

Intervention:

standard treatment, and Moxibustion

Intervention code:

组别:

对照组

样本量:

35

Group:

Control group

Sample size:

干预措施:

标准治疗+假灸

干预措施代码:

001

Intervention:

standard treatment and sham moxibustion

Intervention code:

样本总量 Total sample size : 70

研究实施地点:

Countries of recruitment
and research settings:

国家:

中国

省(直辖市):

广东

市(区县):

深圳

Country:

China

Province:

Guangdong

City:

Shenzhen

单位(医院):

深圳市宝安区中医院

单位级别:

三级甲等

Institution/hospital:

Traditional Chinese Medicine Hospital of Bao'an District

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

MDS-UPDRS量表

指标类型:

主要指标

Outcome:

MDS-UPDRS scale

Type:

Primary indicator

测量时间点:

治疗前、治疗第2周、治疗第4周、治疗第6周、治疗第8周

测量方法:

量表

Measure time point of outcome:

Before treatment, 2 weeks of treatment, 4 weeks of treatment, 6 weeks of treatment, 8 weeks of treatment

Measure method:

scale

指标中文名:

症状自评量表

指标类型:

主要指标

Outcome:

SCL-90

Type:

Primary indicator

测量时间点:

治疗前、治疗第2周、治疗第4周、治疗第6周、治疗第8周

测量方法:

量表

Measure time point of outcome:

Before treatment, 2 weeks of treatment, 4 weeks of treatment, 6 weeks of treatment, 8 weeks of treatment

Measure method:

scale

指标中文名:

简明疼痛评估量表

指标类型:

主要指标

Outcome:

BPI

Type:

Primary indicator

测量时间点:

治疗前、治疗第2周、治疗第4周、治疗第6周、治疗第8周

测量方法:

量表

Measure time point of outcome:

Before treatment, 2 weeks of treatment, 4 weeks of treatment, 6 weeks of treatment, 8 weeks of treatment

Measure method:

scale

指标中文名:

脑电图

指标类型:

主要指标

Outcome:

EEG

Type:

Primary indicator

测量时间点:

治疗前、治疗后

测量方法:

脑电图检测

Measure time point of outcome:

Before and after treatment

Measure method:

EEG test

指标中文名:

肌电图

指标类型:

主要指标

Outcome:

EMG

Type:

Primary indicator

测量时间点:

治疗前、治疗后

测量方法:

肌电图检测

Measure time point of outcome:

Before and after treatment

Measure method:

EMG test

指标中文名:

帕金森病生存质量量表

指标类型:

主要指标

Outcome:

PDQ-39

Type:

Primary indicator

测量时间点:

治疗前、治疗第2周、治疗第4周、治疗第6周、治疗第8周

测量方法:

量表

Measure time point of outcome:

Before treatment, 2 weeks of treatment, 4 weeks of treatment, 6 weeks of treatment, 8 weeks of treatment

Measure method:

scale

指标中文名:

静息态功能核磁共振

指标类型:

主要指标

Outcome:

RS-fMRI

Type:

Primary indicator

测量时间点:

治疗前、治疗后

测量方法:

功能核磁共振检测

Measure time point of outcome:

Before and after treatment

Measure method:

Peripheral blood

指标中文名:

疲劳严重度量表

指标类型:

主要指标

Outcome:

FSS

Type:

Primary indicator

测量时间点:

治疗前、治疗第2周、治疗第4周、治疗第6周、治疗第8周

测量方法:

量表

Measure time point of outcome:

Before treatment, 2 weeks of treatment, 4 weeks of treatment, 6 weeks of treatment, 8 weeks of treatment

Measure method:

scale

指标中文名:

便秘评分量表

指标类型:

主要指标

Outcome:

Wexner

Type:

Primary indicator

测量时间点:

治疗前、治疗第2周、治疗第4周、治疗第6周、治疗第8周

测量方法:

量表

Measure time point of outcome:

Before treatment, 2 weeks of treatment, 4 weeks of treatment, 6 weeks of treatment, 8 weeks of treatment

Measure method:

scale

指标中文名:

帕金森睡眠量表

指标类型:

主要指标

Outcome:

PDSS

Type:

Primary indicator

测量时间点:

治疗前、治疗第2周、治疗第4周、治疗第6周、治疗第8周

测量方法:

量表

Measure time point of outcome:

Before treatment, 2 weeks of treatment, 4 weeks of treatment, 6 weeks of treatment, 8 weeks of treatment

Measure method:

scale

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

不饱和铁结合力

组织:

外周血

Sample Name:

Unsaturated iron binding force

Tissue:

Primary indicator

人体标本去向

使用后销毁

说明

Fate of sample 

Destruction after use

Note:

标本中文名:

转铁蛋白

组织:

外周血

Sample Name:

Serum iron

Tissue:

Primary indicator

人体标本去向

使用后销毁

说明

Fate of sample 

Destruction after use

Note:

标本中文名:

铁蛋白

组织:

外周血

Sample Name:

Ferritin

Tissue:

Primary indicator

人体标本去向

使用后销毁

说明

Fate of sample 

Destruction after use

Note:

标本中文名:

血清铁

组织:

外周血

Sample Name:

Serum iron

Tissue:

Primary indicator

人体标本去向

使用后销毁

说明

Fate of sample 

Destruction after use

Note:

征募研究对象情况:

正在进行

Recruiting

年龄范围:

最小
Min age years
最大
Max age years

Recruiting status:

Participant age:

性别:

Gender:

男女均可

Both

随机方法(请说明由何人用什么方法产生随机序列):

采用SPSS 22.0统计软件,使用随机数表法将70名PD患者分成2组。

Randomization Procedure (please state who generates the random number sequence and by what method):

SPSS 22.0 statistical software was used to divide 70 PD patients into 2 groups using random number table method.

盲法:

Not stated

Blinding:

Not stated

是否共享原始数据:

IPD sharing:

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

东华数字化医院信息管理系统V7.0

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Donghua Digital Hospital Information Management System V7.0

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录表,电子采集和管理系统

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

(Electronic Data Capture, EDC) (Case Record Form, CRF)

数据管理委员会:

Data Managemen Committee:

Yes

研究计划书或研究结果报告发表信息
(杂志名称、期、卷、页,时间;或网址):

Publication information of the protocol/research results report
(name of the journal, volume, issue, pages, time; or website):

ITMCTR BJ-ICP:07032215-5 Tip: IE8 is recommended Use the system with widescreen display resolution above